CClinicalTrials.gg
Sign In
CompletedNCT00912431Updated Nov 2, 2010

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

A Phase 1 interventional study of ABT-126 and Placebo in Healthy, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-02.

Sponsored by Abbott · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objectives of this study are to determine the cerebrospinal fluid (CSF) levels of ABT-126 and to examine the effects of ABT-126 on exploratory biomarkers after administration of a single does of ABT-126 in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy male or female subjects between 18 and 50 years of age

Exclusion criteria

Exclusion Criteria:

  • History of bleeding disorders or Deep Vein Thrombosis
  • History of spinal surgery
  • History of migraine headaches, or other types of headaches occuring more than 2 times per month, or history of spinal disc disease, or chronic, significant low back pain
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1

    Drug: ABT-126

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • DrugABT-126

    ABT-126 administered on Day 1 of Period 1

  • DrugPlacebo

    Placebo for ABT-126 administered on Day 1 of Period 2

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical examination and neurological examination)

    Time frame: Day 1 thru Day 4 in Periods 1 and 2

  2. Pharmacokinetic samples

    Time frame: Day 1 (up to 24-hour post dose) in Periods 1 and 2

  3. Cerebrospinal Fluid samples

    Time frame: Day 1 (up to 24-hour post dose) in Periods 1 and 2

07

Study locations

1 site
  • Site Reference ID/Investigator# 20761
    Glendale, California 91206, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00912431
Lead sponsor
Abbott
First posted
Jun 3, 2009
Start date
Jun 2009
Primary completion
Aug 2009
Last update
Nov 2, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Abbott

Start the discussion